S. Korea Pharmas Benefit From Scare Over H1N1 Flu As Other Firms Hurt
This article was originally published in PharmAsia News
Executive Summary
South Korea's pharmaceutical industry is benefiting from a growing fear of the H1N1 flu at the same time other industries lose business. When the first two South Korean deaths were attributed to the flu, Green Cross, the nation's only drug maker with H1N1 vaccine production facilities, saw a 15 percent jump in the price of its shares, the limit allowed at the stock market. Green Cross currently is negotiating with the government over the price it is be allowed to charge for the vaccine once it is approved, expected by October. Other drug makers, such as Yuhan, are benefiting from ties to multinational drug makers with flu treatments. (Click here for more
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.